Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.